Abstract
Carcinoma of the prostate is the second most common cause of cancer in men and its incidence has virtually doubled over the last 30 years.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Beland G, Elhilali M, Fradet Y et al. (1990) Randomized study comparing orchiectomy versus orchiectomy and anandron in advanced prostate cancer. Gynecol Endocrinol 4 [Suppl 2]: 81
Bertagna C (1990) Treatment of metastatic prostate cancer with orchiectomy and anandron R (Nilutamide): results of a double-blind study versus orchiectomy and placebo. Gynecol Endocrinol 4 [Suppl 2]: 82
Blackard CE, Byar DP, Jordan WP, Vacurg (1973) Orchiectomy for advanced prostatic carcinoma. Urology 1 (6): 553
Boccardo F (1990) Treatment of prostatic cancer with LH-RH analogues alone or in combination with pure antiandrogens. Gynecol Endocrinol 4 [Suppl 2]: 84
Bookstein R, Shew JY, Chen PL, Scully P, Lee WH (1990) Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247: 712
Carter BS, Epstein JI, Isaacs WB (1990) ras Gene mutations in human prostate cancer. Cancer Res 50: 6830
Crawford ED, Eisenberger MA, McLeod DG et al. (1989) A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321 (7): 419
Crawford ED, Bertagna C, Smith JA et al. (1990) A randomized, controlled clinical trial of leuprolide and anandron versus leuprolide and placebo for advanced prostate cancer. Gynecol Endocrinol 4 [Suppl 2]: 85
De Voogt HJ, Klijn JG, Studer U, Schroeder FG, Sylvester R, de Pauw M, members of the EORTC-GU Group (1990) Comparison of orchidectomy and buserelin combined with anti androgens in the treatment of advanced prostatic cancer. (EORTC-trial 30843). Gynecol Endocrinol 4 [Suppl 2]: 83
Ferrari P, Castagnetti G, Pollastri C, Ferrari G, Tavoni F, Grassi D (1990) LHRH analogue buserelin versus buserelin and flutamide in the treatment of advanced metastatic prostatic carcinoma. Five Years Experience. Gynecol Endocrinol 4 [Suppl 2]: 87
Fleming WH, Hamel A, MacDonald R et al. (1986) Expression of the c-myc protooncogene in human prostatic carcinoma and benign prostatic hyperplasia. Cancer Res 46: 1535
Fourcade O, Carion G, Coloby P, Grise P, Mang P, Soret J, Poteri M (1990) Total androgen blockade in advanced prostate carcinoma: interim report of a double blind study using Zoladex and flutamide. Gynecol Endocrinol 4 [Suppl 4]: 89
Fowler JE Jr, Lau JLT, Ghosh L, Mills SE, Mounzer A (1988) Epidermal growth factor and prostatic carcinoma: an immunohistochemical study. J Urol 139: 857
Haefliger JM (1990) A multicentre randomised trial comparing the LHRH analogue ‘zoladex’ vs ‘zoladex’ in combination with flutamide in the treatment of advanced prostate cancer. Gynecol. Endocrinol. 4 [Suppl 2]: 88
Huggins C, Hodges CV (1941) The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1: 292
Iversen P, Danish Prostatic Cancer Group (1990) Daproca 86-zoladex and flutamide versus orchiectomy for avanced prostatic cancer. Gynecol Endocrinol 4 [Suppl 2]: 88
Labrie F, Dupont A, Giguere M et al. (1987) Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients. J Steroid Biochem 27 (1–3): 525
Lunglmayr G (1989) Casodex (ICI 176, 334), a new, non-steroidal anti-androgen. Early clinical results. Horm Res 32 [Suppl 1]: 77
MacDonald A, Chisholm GD, Habib FK (1990) Production and response of a human prostatic cancer line to transforming growth factor-like molecules. Br J Cancer 62: 579
Mahler C, Pinto de Carvalho A, Smith P, members of the EORTC GU Group (1990) Randomized study of orchiectomy versus zoladex and flutamide in metastatic prostatic cancer. Gynecol Endocrinol 4 [Suppl 2]: 81
Morris GL, Green Dodd J (1990) Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines. J Urol 143: 1272
Neri R, Kassem N (1984) Biological and clinical properties of antiandrogens. In: Bresciani F, King RJB, Lippmann ME, Namer M, Raynaud JP (eds) Hormones and cancer 2: Proceedings of the 2nd international congress on hormones and cancer. Raven, New York, p 507 (Progress in cancer research and therapy, vol 31)
Nesbit RM, Baum WC (1950) Endocrine control of prostatic carcinoma: clinical and statistical survey of 1818 cases. JAMA 143: 1317
Osborne CK, Blumenstein B, Crawford ED et al. (1990) Combined versus sequential chemo-endocrine therapy in advanced prostate cancer: final results of a randomized Southwest Oncology Group Study. J Clin Oncol 8: 1675
Pavone-MacAluso M, De Voogt HJ, Viggiano G et al. (1986). Comparison of diethystilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization For Research On Treatment Of Cancer Urological Group. J Urol 136: 624
Plowman PN, Perry LA, Chard T (1987) Androgen suppression by hydrocortisone without ami-noglutethimide in orchiectomised men with prostatic cancer. Br J Urol 59: 255
Qayum A, Gullick W, Clayton RC, Sikora K, Waxman J (1990) The effects of gonadotrophin releasing hormone analogues in prostate cancer are mediated through specific tumor receptors. Br J Cancer 62: 96
Rijinders AWM, Van der Korput JAGM, Van Steenbrugge GJ, Romijn JC, Trapman J (1985) Expression of cellular oncogenes in human prostatic carcinoma cell lines. Biochem Biophys Res Commun 132 (2): 548
Sogani PC, Ray B, Whitmore WF Jr. (1975) Advanced prostatic carcinoma. Urology VI: 164
Trachtenberg T, Walsh PC (1982) Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer. J Urol 127: 466
Treiger B, Isaacs J (1988) Expression of a transfected v-Harvey-ras oncogene in a Dunning rat prostate adenocarcinoma and the development of high metastatic ability. J Urol 140: 1580
Veterans Administration Cooperative Urological Research Group (1967) Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124: 1011
Viola V, Fromowitz F, Oravez S et al. (1986) Expression of ras oncogene p21 in prostate cancer. N Engl J Med 314: 133
Waxman J (1987) Gonadotrophin hormone releasing analogues open new doors in cancer treatment. Br Med J 295: 1084
Waxman J, Williams G, Sandow J et al. (1988) The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue. Am J Clin Oncol II [Suppl 2]: 152
Waxman J, Sandow J, Abel P, Barton C, Keane P, Williams G (1990) Three-monthly GnRH agonist (Buserelin) for prostatic cancer: Br J Urol 65: 43
White JW (1893) The present position of the surgery of the hypertrophied prostate. Ann Surg 18: 152
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1996 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Waxman, J. (1996). Carcinoma of the Prostate: Science and Treatment. In: Peeling, W.B., Becker, H. (eds) Progress in Diagnostics and Therapy of Prostatic Cancer. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79947-1_4
Download citation
DOI: https://doi.org/10.1007/978-3-642-79947-1_4
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-60195-1
Online ISBN: 978-3-642-79947-1
eBook Packages: Springer Book Archive